Imatinib mesilate inhibits melanogenesis in vitro [11]

British Journal of Dermatology

Volumn 155, Issue 2, 2006, Pages 493-494

  Cario Andre M ^a,b   Ardilouze, L ^a,b   Pain, C ^a,b   Gauthier, Y ^c   Mahon, F X ^a,b   Taieb, A ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; MONOPHENOL MONOOXYGENASE;

CELL PROLIFERATION; DEPIGMENTATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HYPOPIGMENTATION; IN VITRO STUDY; LETTER; MELANOCYTE; MELANOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN TOXICITY; VITILIGO;

ANTINEOPLASTIC AGENTS; CELLS, CULTURED; EPIDERMIS; HUMANS; MELANINS; MELANOCYTES; PIPERAZINES; PYRIMIDINES; TISSUE CULTURE TECHNIQUES; VITILIGO;

EID: 33745879177     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07359.x     Document Type: Letter

References (10)

1. Grossman WJ, Wilson DB. Hypopigmentation from imatinib mesylate (Gleevec). J Pediatr Hematol Oncol 2004; 26: 214.
2. Tsao AS, Kantarjian H, Cortes J et al. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003; 98: 2483-7.
3. Etienne G, Cony-Makhoul P, Mahon FX. Imatinib mesylate and gray hair. N Engl J Med 2002; 347: 446.
4. Gauthier Y, Cario-André M, Lepreux S et al. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br J Dermatol 2003; 148: 95-101.
5. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-45.
6. Spritz RA. Molecular basis of human piebaldism. J Invest Dermatol 1994; 103: S137-40.
7. Richards KA, Fukai K, Oiso N, Paller AS. A novel KIT mutation results in piebaldism with progressive depigmentation. J Am Acad Dermatol 2001; 44: 288-92.
8. Imokawa G. Autocrine and paracrine regulation of melanocytes in human skin and in pigmentary disorders. Pigment Cell Res 2004; 17: 96-110.
9. Gauthier Y, Cario-André M, Lepreux S et al. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? Pigment Cell Res 2003; 16: 322-32.
10. Legros L, Cassuto JP, Ortonne JP. Imatinib mesilate (Glivec): a systemic depigmenting agent for extensive vitiligo? Br J Dermatol 2005; 153: 691-2.